儿童常年性鼻炎特异性舌下免疫治疗的系统评价与荟萃分析
该系统评价与荟萃分析纳入16项研究,评估屋尘螨所致儿童常年性过敏性鼻炎的舌下免疫治疗疗效与安全性。结果显示舌下免疫治疗显著降低总鼻症状评分(SMD -1.73)和总用药评分(SMD -1.21),但轻度不良事件风险略增(RR 1.08)。结论认为舌下免疫治疗有效,但需注意药物不良反应。
要点
- 屋尘螨舌下免疫治疗可显著改善患儿鼻症状和减少用药。
- 舌下免疫治疗组轻度不良事件风险略高于安慰剂组(RR 1.08)。
- 中度和重度不良事件风险与安慰剂组无显著差异。
核心结论
- 屋尘螨舌下免疫治疗可有效缓解儿童常年性过敏性鼻炎的总鼻症状评分和总用药评分,但需注意可能的药物不良反应。
研究设计与样本
- 系统评价与荟萃分析,检索截至2019年的医学文献数据库,最终纳入16项符合标准的研究。
主要发现
- 舌下免疫治疗显著降低总鼻症状评分(SMD -1.73;95% CI,-2.62至-0.84;p=0.0001)。
- 舌下免疫治疗显著降低总用药评分(SMD -1.21;95% CI,-1.75至-0.67;p<0.00001)。
- 与安慰剂相比,舌下免疫治疗组发生轻度不良事件的相对风险为1.08(95% CI,1至1.17;p=0.05)。
- 中度不良事件的相对风险为1.15(95% CI,0.87至1.51;p=0.32)。
- 重度不良事件的相对风险为1.68(95% CI,0.68至4.11;p=0.26)。
临床怎么用
- 对于屋尘螨致敏的常年性过敏性鼻炎患儿,可考虑舌下免疫治疗以改善症状和减少用药。
- 治疗期间应监测不良事件,尤其是轻度不良反应的发生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Allergic rhinitis (AR) is a major public health problem and is increasing worldwide. AR affects children's learning efficiency, sleep quality, and other major aspects of life. Sublingual immunotherapy (SLIT) is effective and safe for children with seasonal AR, but for children with perennial allergic rhinitis (PAR) caused by house dust mites (HDM), its effectiveness and safety is less convincing. METHODS: Medical literature databases up to 2019 were searched for published and unpublished pieces of evidence. Studies were individually screened by 2 reviewers against the eligibility criteria. Primary outcomes were total nasal symptoms scores (TNSS) and total medication scores (TMS). The secondary outcomes were total ocular symptoms scores and adverse events (AEs). Random effect models and fixed-effect models were used to calculate the standard mean difference (SMD) and risk ratio (RR), respectively. RESULTS: We identified 3772 abstracts, of which only 16 studies met our established criteria. SLIT significantly reduced TNSS (SMD -1.73; 95% CI, -2.62 to -0.84; p = 0.0001) and TMS (SMD -1.21; 95% CI, -1.75 to -0.67; p < 0.00001). Compared with children taking placebo, children taking SLIT were 1.08 (95% CI, 1 to 1.17; p = 0.05), 1.15 (95% CI, 0.87 to 1.51; p = 0.32), and 1.68 (95% CI, 0.68 to 4.11; p = 0.26) times more likely to develop mild, moderate, and severe AEs, respectively. CONCLUSION: HDM SLIT can effectively alleviate TNSS and TMS in children with PAR, but care should be taken to avoid harm due to possible adverse drug reactions.
引用
- Chen L, Lei L, Cai Y, et al. Specific sublingual immunotherapy in children with perennial rhinitis: a systemic review and meta-analysis. Int Forum Allergy Rhinol. 2020. PMID: 32329187. doi:10.1002/alr.22589
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。